Improved methods for treating cancer with reduced renal toxicity

Abstract

A method is provided for inhibiting the growth of a tumor in a cancer patient or treating a cancer patient, wherein the cancer patient has renal insufficiency. The method requires the administration of an effective amount of Lipoplatin. A second chemotherapeutic drug can also be administered to the patient. The second chemotherapy can be administered prior to or after the Lipoplatin therapy or simultaneously.

Description

background [0001] The present invention relates generally to the field of solid tumors responsive to platinum therapy. [0002] Cisplatin has been used for more than 30 years and has proven effective against many malignancies, including lung, ovarian, head and neck, gynecological, testicular, and urothelial cancers. Although cisplatin is one of the most important and effective anticancer agents, its toxicity often acts as an inhibitory factor preventing continuous courses of treatment. The main side effect is nephrotoxicity (kidney failure). Other side effects include nausea and vomiting, weakness, and neurotoxicity. [0003] During the past 15-20 years, efforts have been made to find alternatives to cisplatin. The main replacement agent used to be the CDDP analogue (carboplatin). Also, in some malignancies, other new agents have been tested, including taxanes (paclitaxel, docetaxel) and gemcitabine and vinorelbine. There was no nephrotoxicity with these agents, but other...

AI Technical Summary

Problems solved by technology

However, none of these agents were more effective than cisplatin